Have a feature idea you'd love to see implemented?
Let us know!
YMAB Y-mAbs Therapeutics Inc
Price (delayed)
$14.06
Market cap
$626.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$550.12M
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product
Highlights
The gross profit has grown by 5% from the previous quarter and by 4% YoY
The gross margin has grown by 2.5% from the previous quarter and by 2.1% YoY
The EPS has grown by 38% YoY but it has contracted by 14% from the previous quarter
The net income has grown by 37% YoY but it has contracted by 14% from the previous quarter
The quick ratio has plunged by 51% from the previous quarter and by 40% YoY
Y-mAbs Therapeutics's equity has decreased by 9% YoY and by 3.9% from the previous quarter
Key stats
What are the main financial stats of YMAB
Market
Valuations
Earnings
Shares outstanding
44.57M
Market cap
$626.65M
Enterprise value
$550.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.47
Price to sales (P/S)
7.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.36
Revenue
$86.55M
EBIT
-$27.65M
EBITDA
-$27M
Free cash flow
-$12.55M
Per share
Balance sheet
Liquidity
EPS
-$0.56
Free cash flow per share
-$0.29
Book value per share
$2.17
Revenue per share
$1.97
TBVPS
$3.22
Total assets
$144.04M
Total liabilities
$48.7M
Debt
$1.27M
Equity
$95.34M
Working capital
$83.29M
Debt to equity
0.01
Current ratio
2.92
Quick ratio
2.67
Net debt/EBITDA
2.83
Margins
Efficiency
Dividend
EBITDA margin
-31.2%
Gross margin
88.6%
Net margin
-28.4%
Operating margin
-31.9%
Return on assets
-18.8%
Return on equity
-24.9%
Return on invested capital
-113.4%
Return on capital employed
-27.5%
Return on sales
-31.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
YMAB stock price
How has the Y-mAbs Therapeutics stock price performed over time
Intraday
-0.57%
1 week
-0.14%
1 month
5.16%
1 year
173.54%
YTD
106.16%
QTD
6.92%
Financial performance
How have Y-mAbs Therapeutics's revenue and profit performed over time
Revenue
$86.55M
Gross profit
$76.7M
Operating income
-$27.65M
Net income
-$24.61M
Gross margin
88.6%
Net margin
-28.4%
The company's net margin rose by 38% YoY but it fell by 11% QoQ
The net income has grown by 37% YoY but it has contracted by 14% from the previous quarter
The operating margin has grown by 35% YoY but it has contracted by 7% from the previous quarter
YMAB's operating income is up by 34% year-on-year but it is down by 10% since the previous quarter
Growth
What is Y-mAbs Therapeutics's growth rate over time
Valuation
What is Y-mAbs Therapeutics stock price valuation
P/E
N/A
P/B
6.47
P/S
7.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.36
The EPS has grown by 38% YoY but it has contracted by 14% from the previous quarter
YMAB's P/B is 44% above its last 4 quarters average of 4.5 and 6% above its 5-year quarterly average of 6.1
Y-mAbs Therapeutics's equity has decreased by 9% YoY and by 3.9% from the previous quarter
The stock's price to sales (P/S) is 38% more than its last 4 quarters average of 5.2
YMAB's revenue is up by 2.4% since the previous quarter
Efficiency
How efficient is Y-mAbs Therapeutics business performance
The company's return on invested capital has surged by 73% YoY but it fell by 7% QoQ
The ROS has grown by 35% YoY but it has contracted by 7% from the previous quarter
Y-mAbs Therapeutics's ROA has increased by 33% YoY but it has decreased by 11% from the previous quarter
Y-mAbs Therapeutics's return on equity has increased by 32% YoY but it has decreased by 16% QoQ
Dividends
What is YMAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for YMAB.
Financial health
How did Y-mAbs Therapeutics financials performed over time
Y-mAbs Therapeutics's total assets is 196% more than its total liabilities
The total liabilities has soared by 102% from the previous quarter and by 76% YoY
The current ratio has plunged by 53% from the previous quarter and by 39% YoY
The company's debt is 99% lower than its equity
Y-mAbs Therapeutics's equity has decreased by 9% YoY and by 3.9% from the previous quarter
The company's debt rose by 8% QoQ and by 2.3% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.